Atara Biotherapeutics, Inc. (ATRA) |
|
7.31 -0.04 (-0.54%)
|
06-26 21:38 |
|
Open: |
7.4 |
Pre. Close: |
7.35 |
|
High:
|
7.68 |
Low:
|
7.1 |
|
Volume:
|
2,360,013 |
Market Cap:
|
683(M) |
|
|
|
|
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.68 - 7.72 |
7.72 - 7.75 |
|
Low:
|
7.01 - 7.05 |
7.05 - 7.08 |
|
Close:
|
7.25 - 7.31 |
7.31 - 7.36 |
|
Technical analysis |
as of: 2022-06-24 4:38:10 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 8.97  One year: 10.47 |
| Support: |
Support1: 5.78 Support2: 4.61 |
| Resistance: |
Resistance1: 7.67 Resistance2: 8.97 |
| Pivot: |
5.87 |
| Moving Average: |
MA(5): 6.75 MA(20): 5.66
MA(100): 8.42  MA(250): 12.69 |
| MACD: |
MACD(12,26): 0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 92 %D(3): 91.3 |
| RSI: |
RSI(14): 67.3 |
| 52-week: |
High: 20.04 Low: 4.61 |
| Average Vol(K): |
3-Month: 1,138 (K) 10-Days: 1,520 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATRA ] has closed below upper band by 1.9%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 24 Jun 2022
Is Atara Biotherapeutics Inc (ATRA) a Leader in the Healthcare Sector? - InvestorsObserver
Thu, 23 Jun 2022
Building Revolutionary Solidarity Across the Americas Against the Failed “Summit of the Americas” – Liberation News - Liberation
Wed, 22 Jun 2022
Bloomberg-Funded AGs Push Climate Cases Targeting Domestic Energy Producers – InsideSources - InsideSources
Fri, 17 Jun 2022
Will Business Expansion Plans Aid FEMSA's (FMX) Stock Growth? - Yahoo Finance
Fri, 17 Jun 2022
Atara Biotherapeutics (NASDAQ:ATRA) Shares Gap Up to $5.05 - Defense World
Fri, 10 Jun 2022
Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer | Scientific Reports - Nature.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
90 (M) |
|
% Held by Insiders
|
6.991e+007 (%) |
|
% Held by Institutions
|
0.5 (%) |
|
Shares Short
|
9,730 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.3103e+008 |
|
EPS Est Next Qtl
|
-1.08 |
|
EPS Est This Year
|
-3.92 |
|
EPS Est Next Year
|
-4.37 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
673.8 |
|
Return on Equity (ttm)
|
-40.3 |
|
Qtrly Rev. Growth
|
2.034e+007 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-50.66 |
|
EBITDA (p.s.)
|
1.12376e+007 |
|
Qtrly Earnings Growth
|
-3.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-221 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.15 |
|
Price to Cash Flow
|
3.76 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.179e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
